

MDS Publications

Publications (Co-authors)

1. Synthesis and structural characterization of ricin inhibitors targeting ribosome binding using fragment-based methods and structure-based design. N. Tumer in revision in *J Med Chem*
2. Conserved Bone Morphogenetic Protein signaling regulates cancer metabolism through AMPK and PI3K crosstalk. J. Langenfeld, Submitted to *Molecular Cancer*.
3. Carry, E.; Kshatriya, D.; Silva, J.; Davies, D. L.; Yuan, B.; Wu, Q.; Patel, H.; Park, E. R.; Gilleran, J.; Hao, L.; Roberge, J.; Bello, N. T.; Simon, J. E. Identification of Dihydromyricetin and Metabolites in Serum and Brain Associated with Acute Anti-Ethanol Intoxicating Effects in Mice. *International Journal of Molecular Sciences* **2021**, *22*, 7460.
4. Silva, J.; Carry, E.; Xue, C.; Zhang, J.; Liang, J.; Roberge, J. Y.; Davies, D. L. A Novel Dual Drug Approach That Combines Ivermectin and Dihydromyricetin (DHM) to Reduce Alcohol Drinking and Preference in Mice. *Molecules* **2021**, *26*, 1791.
5. Gilleran, J. A.; Yu, X.; Blayney, A. J.; Bencivenga, A. F.; Na, B.; Augeri, D. J.; Blanden, A. R.; Kimball, S. D.; Loh, S. N.; Roberge, J. Y.; Carpizo, D. R. Benzothiazolyl and Benzoxazolyl Hydrazones Function as Zinc Metallochaperones to Reactivate Mutant p53. *Journal of Medicinal Chemistry* **2021**.
6. da, S.-D. V.; Cao, B.; Alasadi, A.; Tao, H.; Jin, S.; Lanco, O.; Chiles, E.; Aleksandrova, M.; Luo, S.; Singh, A.; Khiabani, H.; Su, X.; Herranz, D.; Augeri, D. J.; Minuzzo, S.; Indraccolo, S. A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia. *Blood* **2021**.
7. Alasadi, A.; Cao, B.; Guo, J.; Tao, H.; Collantes, J.; Tan, V.; Su, X.; Augeri, D.; Jin, S. Mitochondrial uncoupler MB1-47 is efficacious in treating hepatic metastasis of pancreatic cancer in murine tumor transplantation models. *Oncogene* **2021**, *40*, 2285-2295.
8. Zaman, S.; Yu, X.; Bencivenga, A. F.; Blanden, A. R.; Liu, Y.; Withers, T.; Na, B.; Blayney, A. J.; Gilleran, J.; Boothman, D. A.; Loh, S. N.; Kimball, S. D.; Carpizo, D. R. Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding. *Molecular Cancer Therapeutics* **2019**, *18*, 1355-1365.
9. NeMoyer, R.; Mondal, A.; Langenfeld, E.; Scott, M.; Langenfeld, J.; Vora, M.; Rongo, C.; Glover, D.; Lairson, L.; Augeri, D. J.; Peng, Y.; Jabbour, S. K. Targeting bone morphogenetic protein receptor 2 sensitizes lung cancer cells to TRAIL by increasing cytosolic Smac/DIABLO and the downregulation of X-linked inhibitor of apoptosis protein. *Cell Commun Signal* **2019**, *17*, 150.
10. Na, B.; Yu, X.; Withers, T.; Gilleran, J.; Yao, M.; Foo, T. K.; Chen, C.; Moore, D.; Lin, Y.; Kimball, S. D.; Xia, B.; Ganesan, S.; Carpizo, D. R. Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation. *npj Breast Cancer* **2019**, *5*, 1-10.
11. Augeri, D. J. In *Academic drug discovery research at Rutgers University, Piscataway, New Jersey, 2019*; American Chemical Society: 2019; pp BMGT-0013.
12. Yu, X.; Kogan, S.; Chen, Y.; Tsang, A. T.; Withers, T.; Lin, H.; Gilleran, J.; Buckley, B.; Moore, D. F.; Bertino, J. R.; Chan, C. S.; Kimball, S. D.; Loh, S. N.; Carpizo, D. R. Zinc metallochaperones reactivate mutant p53 using an ON/OFF switch mechanism: a new paradigm in cancer therapeutics. *Clin. Cancer Res.* **2018**, *24*, 4505-4517.
13. Newman, J. H.; Chesson, C. B.; Dobias, N. S.; Bommarreddy, P. K.; Marshall, S. R.; Li, S.; Zloza, A.; Augeri, D. J.; NeMoyer, R.; Lee, M. J.; Tarabichi, S.; Zloza, A.; Malhotra, J.; Langenfeld, E.; Langenfeld, J.; Jhavar, S. R.; Jabbour, S. K.; Sadimin, E. T.; Minerowicz, C.; Carayannopolous, M. O.; Kerrigan, J. E.; Goedken, M. Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer. *Oncogene* **2018**, *37*, 3672-3685.
14. Yu, X.; Blanden, A.; Tsang, A. T.; Zaman, S.; Liu, Y.; Gilleran, J.; Bencivenga, A. F.; Kimball, S. D.; Loh, S. N.; Carpizo, D. R. Thiosemicarbazones Functioning as Zinc Metallochaperones to Reactivate Mutant p53. *Molecular Pharmacology* **2017**, *91*, 567-575.
15. Bartucci, M.; Hussein, M. S.; Huselid, E.; Flaherty, K.; Patrizii, M.; Laddha, S. V.; Kui, C.; Bigos, R. A.; Gilleran, J. A.; El Ansary, M. M. S.; Awad, M. A. M.; Kimball, S. D.; Augeri, D. J.; Sabaawy, H. E. Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma. *Targeted Oncology* **2017**, *12*, 449-462.
16. Augeri, D. J.; Langenfeld, E.; Castle, M.; Gilleran, J. A.; Langenfeld, J. Inhibition of BMP and of TGF β receptors downregulates expression of XIAP and TAK1 leading to lung cancer cell death. *Mol. Cancer* **2016**, *15*, 27/1-27/16.
17. Blanden, A. R.; Yu, X.; Wolfe, A. J.; Gilleran, J. A.; Augeri, D. J.; O'Dell, R. S.; Olson, E. C.; Kimball, S. D.; Emge, T. J.; Movileanu, L.; Carpizo, D. R.; Loh, S. N. Synthetic Metallochaperone ZMC1 Rescues Mutant p53 Conformation by Transporting Zinc into Cells as an Ionophore. *Molecular Pharmacology* **2015**, *87*, 825-831.
18. Augeri, D. J.; Kimball, S. D.; Yu, X.; Gilleran, J. A.; Blanden, A. R.; Loh, S. N.; Carpizo, D. R. In *Zinc-metallochaperone complexes that restore wildtype structure and function of mutant p53 in cancer*, 2015; American Chemical Society: 2015; pp MEDI-533.
19. Yu, X.; Blanden, A. R.; Narayanan, S.; Jayakumar, L.; Lubin, D.; Loh, S. N.; Augeri, D.; Kimball, S. D.; Carpizo, D. R. Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism. *Oncotarget* **2014**, *5*, 8879-92.